Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript November 6, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $2.02, expectations were $1.53. Operator: Good ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Daina Graybosch’s rating is based on Gilead Sciences’ strong financial performance and promising pipeline developments. The company reported impressive third-quarter results, with both revenue and ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market cap of $114.2 billion. Gilead specializes in developing and delivering ...

MISSISSAUGA — Gilead Sciences Canada, Inc. (Gilead Canada) announced that Paul Petrelli joined the organization as Vice ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. “Gilead’s third quarter results are the strongest o ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.

For the full year, Gilead now expects earnings per-share between 5 cents to 25 cents, compared with its prior view of zero cents to 30 cents. On an adjusted basis, the company expects earnings per ...